A
0.231
0.00 (-0.43%)
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bullish |
| Biotechnology (Global) | Mixed | Bullish | |
| Stock | AEON Biopharma, Inc. | - | - |
AIStockmoo Score
| Analyst Consensus | 0.0 |
| Insider Activity | NA |
| Price Volatility | 1.9 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | 0.0 |
| Relative Valuation | NA |
| Financial Health | -3.5 |
| Macro Environment | -2.8 |
| AI Insight | NA |
| AI Technical | NA |
| Weighted Average | -0.03 |
Select this tab to load the latest available analysis.
|
AEON Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on developing botulinum toxins. It develops ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, which completed a Phase 2 study for the treatment of cervical dystonia and has an ongoing Phase 2 study for the treatment of both chronic and episodic migraine. AEON Biopharma, Inc. is based in Irvine, California. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| % Held by Insiders | 24.46% |
| % Held by Institutions | 14.66% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Beacon Wealthcare Llc | 30 Sep 2026 | 12,856 |
No data within this time range.
No data within this time range.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |